Robert E. Gagnon - 02 Sep 2025 Form 4 Insider Report for Opus Genetics, Inc. (IRD)

Reporting relationship: Chief Financial Officer
Issuer ticker: IRD
Reported as of: 02 Sep 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 11 Sep 2025, 18:03:52 UTC
Prior SEC filing: 18 Jul 2025
Next SEC filing: 18 Sep 2025
Source filing: View source filing
Reporting owner signature: /s/ Amy Rabourn, by Power of Attorney

Key filing fact

Robert E. Gagnon filed Form 4 for Opus Genetics, Inc. (IRD) on 11 Sep 2025.

Key facts

This page summarizes Robert E. Gagnon's Form 4 filing for Opus Genetics, Inc. (IRD).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 11 Sep 2025, 18:03.

Change

Previous filing in this sequence was filed on 18 Jul 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001504983 Primary reporting owner

Gagnon Robert E.

Relationship: Chief Financial Officer
Address: C/O OPUS GENETICS, INC., 8 DAVIS DRIVE, SUITE 220, DURHAM
Signature: /s/ Amy Rabourn, by Power of Attorney
Signature date: 11 Sep 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IRD transaction

Common Stock

Award

Transaction value: $0
Shares: +200,000
Change %
Price: $0.000000
Shares after: 200,000
Date: 10 Sep 2025
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IRD transaction Derivative

Employee Stock Option (right to buy)

Award

Transaction value: $0
Shares: +250,000
Change %
Price: $0.000000
Shares after: 250,000
Date: 02 Sep 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 250,000
Exercise price: $1.23
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents a grant of restricted stock units which vest with respect to 25% on September 2, 2026, with the remaining shares vesting in equal monthly installments on the last day of each full month over the next thirty-six (36) months, subject to the Reporting Person's continuing service.

Footnote F2

The option will vest with respect to 25% on September 2, 2026, with the remaining shares vesting in equal monthly installments on the last day of each full month over the next thirty-six (36) months, subject to the Reporting Person's continuing service.